We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Sanofi’s Dupixent has been granted FDA priority review for the treatment of bullous pemphigoid (BP), a chronic skin disease. If approved, Dupix ...